Next Article in Journal
Analysis of Synergism between Extracellular Polysaccharide from Bacillus thuringensis subsp. kurstaki HD270 and Insecticidal Proteins
Previous Article in Journal
Assessing Larval Zebrafish Survival and Gene Expression Following Sodium Butyrate Exposure and Subsequent Lethal Bacterial Lipopolysaccharide (LPS) Endotoxin Challenge
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Toxins
Volume 15
Issue 10
10.3390/toxins15100589
toxins-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

The Health Status of Horses Used for at Least Six Complete Cycles of Loxoscelic Antivenom Production

by
Ana Luísa Soares de Miranda
1,
Bruno Cesar Antunes
2,
João Carlos Minozzo
2,
Sabrina de Almeida Lima
3,
Ana Flávia Machado Botelho
4,
Marco Túlio Gomes Campos
1,
Carlos Chávez-Olórtegui
3 and
Benito Soto-Blanco
1,*
1
Department of Veterinary Clinics and Surgery, Veterinary College, Universidade Federal de Minas Gerais (UFMG), Av. Antônio Carlos 6627, Belo Horizonte 30123-970, MG, Brazil
2
Department of Health of the State of Paraná, Centro de Produção e Pesquisa de Imunobiológicos (CPPI), Rua Piquiri 170, Piraquara 80230-140, PR, Brazil
3
Department of Biochemistry and Immunology, Institute of Biological Sciences, Universidade Federal de Minas Gerais (UFMG), Av. Antônio Carlos 6627, Belo Horizonte 31270-901, MG, Brazil
4
Department of Veterinary Medicine, Veterinary College, Universidade Federal de Goiás (UFG), Campus Samambaia, Goiânia 74690-900, GO, Brazil
*
Author to whom correspondence should be addressed.
Toxins 2023, 15(10), 589; https://doi.org/10.3390/toxins15100589
Submission received: 4 August 2023 / Revised: 21 September 2023 / Accepted: 24 September 2023 / Published: 26 September 2023
(This article belongs to the Section Animal Venoms)
Browse Figures
Versions Notes

Abstract

:
Antivenom production against Loxosceles venom relies on horses being immunized and bled for plasma harvest. One horse can partake in several cycles of antivenom production, which will require years of constant venom and adjuvant inoculation and bleeding. The actual impact on the health of horses that participate in several antivenom-producing cycles is unknown. Therefore, this study aimed to evaluate the general health status of horses that underwent at least six cycles of loxoscelic antivenom production. Seven crossbred horses that had partaken in six to eight complete antivenom-producing cycles were used and established as the immunized group (IG). Under the same handling and general management, eleven horses were established as the control group (CG). The horses were evaluated regarding their general clinical status and had their blood sampled, and an ECG recorded. The IG presented lower RBC and PCV, despite keeping values within inferior limits for the species. Renal function was not impaired, and liver-related enzymes were higher than those in the CG, probably due to liver exertion from immunoglobulin synthesis. ECG showed some abnormalities in the IG, such as atrioventricular block and a wandering atrial pacemaker, corroborated by an increase in CK-MB. The cardiovascular abnormalities were mainly found in the horses that participated in several antivenom-producing cycles. The overall results indicate that these horses had some impairment of their general health status. Once available, some alternative, less toxic antigens should replace the venom for immunization of horses used for antivenom production.
Keywords:
antisera production; brown spider; dermonecrosis; loxoscelism; safety evaluation
Key Contribution: Horses are used to produce the antivenom used to treat envenomation. This study shows the influences on horses’ health induced by the immunization protocol for antivenom production used for the treatment of dermonecrotic lesions induced by brown spider (Loxosceles spp.) bites. To improve the welfare of horses, a less toxic antigen should replace the venom in the induction of antibody synthesis for antivenom production as soon as it becomes available. Less toxic options for the venom are in an advanced stage of study and will possibly soon be available for use.

1. Introduction

Antivenom remains the most suitable treatment for loxoscelism, a syndrome triggered by the bite from a brown spider (Loxosceles spp.) [1,2,3]. The most common manifestation of loxoscelism is cutaneous, and consists of a progressive dermonecrotic lesion with gravitational spreading. To a lesser extent, loxoscelism can manifest as a visceral cutaneous form consisting of systemic hemolysis, intravascular coagulation, and acute renal failure, often leading to death [4,5,6,7]. The venom produced by Loxosceles spiders is a mixture of several toxins. Sphingomyelinases D are considered the main toxins of the venom; these enzymes improve inflammation and local tissue injury by cleaving tissue phospholipids [8,9]. Other important toxins are hyaluronidases, which enhance the spread of venom toxins [10]; astacin-like metalloproteases, which hydrolyze the extracellular matrix [11]; and translationally controlled tumor proteins and Loxosceles allergen-like toxins, which trigger the release of histamine [12,13]. Loxosceles venom contains several other toxins of almost unknown toxic action [9].
Antivenom production is based on immunizing animals, harvesting their blood, purifying it, and procuring an immunobiological solution filled with immunoglobulins to counteract and neutralize the harmful effects of envenomation [14,15,16,17,18,19]. Despite its obvious public health importance, antivenom procurement faces several hindrances, ranging from venom extraction to animal welfare [16,17,20,21], especially in Brazil, where antivenom in loxoscelism is primarily employed [2,22]. Animal welfare discussions focus mainly on horses because they are the primary species used for antivenom procurement [14,18,21,23,24]. Hyperimmunization and multiple immunization protocols to produce Loxosceles antivenom can have several adverse effects on horses, such as ulcers, abscesses, and renal failure [21,25]. However, no further studies have focused on the actual clinical impact on the horses’ health, not only regarding the systemic effects of the venom but also on the impact of partaking in several consecutive immunization protocols, which consist of animals undergoing systematic bleeding, physical restraint, and stress.
Therefore, this study aimed to evaluate the general health status of horses used in six or more immunization cycles for loxoscelic antivenom procurement, comparing clinical, hematological, and electrocardiographic findings with those of non-immunized horses.

2. Results

2.1. Clinical Findings

All horses presented satisfactory clinical conditions because no significant clinical alterations were diagnosed. Some horses from the CG, mainly colts and fillies, required a twitch to ensure the handler’s safety. This restraining method might explain why horses from the CG, despite their lack of statistical significance, presented higher heart rates (HR) (56.0 ± 3.80 bpm) than those from the IG (45.9 ± 5.81 bpm). Multiple subcutaneous abscesses (Figure 1) and bilateral thrombophlebitis were observed in the IG horses but not in the controls. Furthermore, all horses from the IG presented with lymphadenopathy. Mandibular, parotid, retropharyngeal, superficial cervical, and ischiatic lymph nodes were palpable, with increased temperature and slight sensibility. No horse from the CG presented any lymph node enlargement.

2.2. Electrocardiographic Findings

All horses in the CG presented normal sinus rhythm. Of the seven horses of the IG, six presented some conduction abnormalities, such as first-degree AV block (Figure 2A) (42.9%), polymorphic ventricular tachycardia (14.29%), wandering atrial pacemaker (14.3%) (Figure 2B), second-degree AV block (14.3%) (Figure 2C), sinus tachycardia (14.3%), and sinus arrhythmia (14.3%).
Results from the ECG recordings are presented in Table 1. Only QT intervals and T waves showed statistical significance. The QT interval was higher in the IG horses than in the CG horses, whereas T waves showed higher values in the CG horses.

2.3. Hematologic Analyses

Results from the CBC are presented in Table 2. The IG horses showed significantly lower values of RBC, and higher values of MCV, RDW-SD, RDW-CV, and P-LCR, than the CG horses.

2.4. Biochemical Analyses

The main blood biochemical parameters obtained between the experimental groups are presented in Table 3. ALT, AST, GGT, and ALP showed statistical significance between experimental groups, with the IG presenting the highest values but within reference ranges for the species. Albumin and triglyceride levels were higher in the CG horses than in the IG horses. Horses from the IG showed CK activities of 386.4 ± 65.2 U/L (reference: 90.0–270.0 U/L), and CK-MB activities of 318.2 ± 60.5 U/L (reference: 5.0–25.0 U/L).

3. Discussion

3.1. Clinical Findings

The significant clinical changes observed in immunized horses were the presence of multiple subcutaneous abscesses, bilateral thrombophlebitis, and lymphadenopathy. None of these alterations were seen in the CG because no horses had been in contact with adjuvants, venom, inoculations, or bleeding procedures. Subcutaneous abscesses have already been described in horses that underwent the immunization protocol using Loxosceles venom [21], and occurred mainly due to the use of adjuvants and the inflammatory response caused by the immunization protocol [26]. Similarly, thrombophlebitis occurred because of systematic venipunctures on the external jugular vein that horses from the IG had undergone [27,28,29,30].
All horses from the IG presented with lymphadenopathy, whereas none of the horses from the CG presented with any lymph node enlargement. Lymphadenopathy is notable in horses with a general inflammatory process [31,32]. Lymph nodes are clusters of germinal cells within a connective tissue framework, containing lymphocytes and macrophages in proximity, which play a vital role in the immune response. Inflammation, such as that incited by the adjuvants and venom used in the present study, can cause lymphadenopathy due to lymphocyte proliferation and accumulation of antigenic materials [33].

3.2. Electrocardiographic Findings

L. intermedia venom has a direct cardiotoxic effect in isolated, perfused heart preparations and ventricular cardiac myocytes [34]. Thus, the heart function of the horses in this study was evaluated via ECG. The ECG findings in the horses from this study were first-degree AV block in three horses (42.9%), polymorphic ventricular tachycardia, wandering atrial pacemaker, second-degree AV block, sinus tachycardia, and sinus arrhythmia in a horse (14.3%). These ECG abnormalities do not affect the horses’ performance [35,36]. First-degree AV block is a common finding in horses’ ECG because of the higher vagal tone of the species, and can disappear after exercise [31]. This conduction abnormality is diagnosed when the PR interval exceeds 0.2 s; therefore, the conduction from the sinus node to the ventricles is prolonged [35]. Clinical significance, however, is noted only when the PR intervals are significantly prolonged (by over 0.5 s) [37,38]. First-degree AV block was the main finding in the ECGs of this study because it encompassed over 42% of the animals evaluated. Despite the PR increase (but all under 0.5 s), no clinical significance of this finding was highlighted, corroborating its possible physiological origin.
Second-degree AV block is also frequent in clinically healthy horses at rest [37,38,39,40], which is attributed to fluctuations in the autonomic tone, as horses naturally exhibit a high vagal tone [31]. Wandering atrial pacemakers can be caused by a higher vagal tone, a physiological finding that has been previously described by several authors [36,39,41,42]. Sinus arrhythmia can usually be diagnosed in horses at rest because of their high vagal tone. Sinus tachycardia, if not accompanied by other clinical findings, might be related to excitement due to handling or stress [31,35,39].
Polymorphic ventricular tachycardia is defined by four or more consecutive ventricular beatings and can be indicative of primary myocardial disease, hypoxia, or electrolyte imbalance [42,43], and was described in rattlesnake envenoming [44]. Clinical signs of congestive heart failure should be observed because they become more severe over time because of shorter cycle lengths, higher heart rates, and polymorphic ventricular rhythm. Polymorphic ventricular tachycardia is associated with increased electrical inhomogeneity and instability, thus increasing the risk of developing a fatal rhythm [45,46,47].
The QT intervals and T waves showed statistical significance. The QT interval represents cardiac repolarization, and an increase was observed in the IG compared with the CG. The QT might be influenced to some extent by HR, body weight, sex, autonomic tone, and environment. Horses may present a considerable interbreed variation for this variable [48], which explains the difference observed in this study. All horses were crossbreeds, and the CG comprised younger horses. Despite this statistical difference, it is essential to highlight that both experimental groups maintained QT values within the reference range for the species, and no relevant clinical finding was correlated with this parameter variation. It is important to emphasize that an increase in the QT interval predicts ventricular arrhythmias [48,49,50]; therefore, animals showing this finding must be monitored. Regarding T waves, higher values were observed in the CG horses. The T wave might be correlated to hyperkalemia or myocarditis, but only when extreme values (>1.4 mV) are observed, which was not the case in the present study [37,40].

3.3. Hematologic Analyses

Despite remaining within the reference values of the species, the IG horses maintained hematological variables such as RBC and PCV on inferior limits. Age can be a relevant factor that can influence these parameters, and horses from the IG evaluated here were 15 years old or older, whereas those of the CG ranged from 5 to 8 years old. The reduction in the RBC count with a compensatory increase in MCV in older horses is probably due to the impaired regenerative capacity of the bone marrow of geriatric horses [51,52]. In this study, MCV was superior in the IG compared with the CG. Thus, these horses might present some anemia, perhaps due to partaking in numerous and systematic bleedings for antivenom procurement, as well as an impaired regenerative bone marrow capacity.
A slight neutrophilia pattern was observed in the IG, possibly due to the several immunization protocols these horses had undergone, with the effects of adjuvants and venom toxicity [21]. Neutrophils were largely recruited in acute inflammation [53], so thrombophlebitis and subcutaneous abscesses in the IG horses might contribute to this discrete neutrophilia.

3.4. Biochemical Analyses

All enzymes related to liver function (ALT, AST, GGT, and ALP) showed statistically higher values in the IG horses, but these values were within reference ranges for the species. Horses used for antivenom production have a higher hepatic demand because the liver is responsible for globulin synthesis [54]. However, only severe increases exceeding the upper reference limits of these enzymes indicate a dysfunction or impairment [53], which was not the case. Similar results were obtained in horses used for snake antivenom production [18]. On the other hand, no apparent kidney impairment occurred in the horses in the present study, in which urea and creatinine were kept within reference ranges and had no statistical significance between the IG and the CG. This finding is similar to that of horses used for snake antivenom production [18].
IG horses presented significantly lower albumin levels than the CG. A decrease in albumin levels (but maintenance within physiological ranges) in horses used for antivenom production has been previously described [18,54]. A decrease in albumin production might be correlated to inflammation [55], a reaction to which horses of the IG have systematically been exposed. The induction of cytokines, especially IL1, IL6, and TNF-α, acts on the liver to produce new acute phase proteins, such as serum amyloid A and fibrinogen [55].
Triglycerides were also significantly higher in the CG horses, and some animals in this group presented triglycerides above reference values for the species. These horses presented higher body scores and weights than IG horses and had visible adiposity deposits, such as neck crests, which might explain their higher triglyceride levels and a higher cholesterol tendency [56].
The measurement of CK-MB is used to detect myocardial injuries (CK-MB) [57]. Horses in the IG showed CK activities of 386.4 ± 65.2 U/L (reference: 90.0–270.0 U/L) and CK-MB activities of 318.2 ± 60.5 U/L (reference: 5.0–25.0 U/L). Because CK-MB is a fraction of total CK, a CK increase might be correlated solely with the CK-MB increase because of the extremely high levels of CK-MB presented here.
Increased CK-MB can be caused by myocardial injury [58,59], although some studies have shown that an increase in CK-MB does not reflect in a histological lesion and comes from a transitory increase in sarcolemma permeability [60,61]. In this study, bleeding for antivenom production may have caused transient ischemia, and thus caused the myocardial injury reflected in the ECG alterations and CK-MB elevation. In addition to bleeding, some toxins of the Loxosceles venom could exert cardiotoxicity. This venom caused impairment of cardiac function due to calcium flow disruption and its increased intracellular concentration [34], which might explain the high level of rhythm abnormalities in the ECG recordings and increased CK-MB observed in the present study.

3.5. Limitations and Perspectives

All horses used in this study were at the end of their use for loxoscelic antivenom production and would no longer be used for this purpose. These horses were used for six to eight complete immunization cycles. This variation in the number of cycles was due to individual antibody titration responses against the venom; therefore, it was necessary to repeat the immunization when the titer was insufficient to produce the antivenom. The ideal would be to be able to monitor the animals throughout the entire period of use as producers of antibodies against the venom, with another group of the same number of animals kept under the same conditions to serve as a control. Despite the limitations of the present study, it was possible to verify that horses subjected to six to eight complete loxoscelic immunization protocols showed some impairment in their general health status. To improve the welfare of horses, a less toxic antigen should replace the venom for immunization.
As using venom for the immunization of horses was responsible for damage to their health, one suggestion is to use non-toxic antigens that can induce the formation of antibodies that neutralize the Loxosceles venom toxins. Some recombinant toxins, especially sphingomyelinases isoforms, were synthesized and induced the production of neutralizing antibodies, but these recombinant toxins were not entirely non-toxic to the immunized animals [2]. Thus, some chimeric proteins containing multiepitopes for Loxosceles toxins were developed to immunize animals without causing major health damage while efficiently producing neutralizing antibodies [62,63]. However, the use of animals may, in the future, be replaced using in vitro laboratory methods to produce large amounts of neutralizing antibodies. Currently, the most viable strategy for obtaining specific neutralizing antibodies for Loxosceles antivenom is their production via hybridoma cell cultures [64]. Hybridomas are formed by spleen B cells of immunized animals fused to myeloma cells [65]. This technology has the advantage of not using animals for antibody production, but it is not yet fully developed for commercial antivenom production.

4. Conclusions

Horses used in six to eight loxoscelic immunization protocols showed multiple subcutaneous abscesses, bilateral thrombophlebitis, lymphadenopathy, and cardiovascular abnormalities. Biochemical analyses detected no significant kidney or liver dysfunction. Overall, the results indicate that these horses had some impairment of their general health status. Once available, alternative, less toxic antigens should replace the venom used for immunization of horses for antivenom production.

5. Materials and Methods

5.1. Animals and Experimental Groups

The institutional Ethical Committee for the Use of Animals of the Federal University of Minas Gerais approved the animal study protocol (protocol code 159/2019, approved on 4 June 2018).
Eighteen healthy crossbred horses, both male and female, weighing 501.86 ± 95.29 Kg and 18.86 ± 3.34 years of age, were used. Horses were housed in the Centro de Produção e Pesquisa de Imunobiológicos (CPPI—Center of Production and Research of Immunobiologicals), Piraquara, Paraná, Brazil. Horses were kept at pasture and were fed 6 kg of alfalfa hay, 2 kg of hydrated/germinated oat grains per day, and 2 kg of horse ration containing 12% protein. Water and mineral salt were provided ad libitum. Horses were vaccinated yearly against encephalomyelitis, influenza, leptospirosis, rabies, strangles, and tetanus. All horses were purchased from certified properties free from infectious equine anemia and glanders.
Seven of these horses underwent six to eight complete immunization cycles for loxoscelic antivenom production and were named the immunized group (IG). These animals were at the end of loxoscelic antivenom production and would no longer be used for this purpose. This variation in the number of immunization cycles was due to individual antibody titration responses against the venom; therefore, it was necessary to repeat the immunization when the titer was insufficient to produce the antivenom. The venom used for the immunization was a pool of venom collected from L. intermedia, L. gaucho, and L. laeta specimens captured within the Paraná and Santa Catarina States, Brazil. These horses’ first immunization protocol was described earlier [21], and the consecutive ones consisted only of reimmunization cycles because hyperimmunization is performed only once during the horses’ lives. When the horses acquired a satisfactory immunoglobulin titrate, bleeding for antivenom industrial procurement was performed. When the horses were evaluated in this experiment, they had not undergone any bleeding or immunization for at least 60 days, and some had already retired from their activities.
For the control group (CG), eleven naïve horses were used. These horses were not used for any immunization protocol but were maintained under the same nutritional and general management as the IG horses. They were ready to start the loxoscelic antivenom production process and were monitored in another study [21].

5.2. Clinical, Electrocardiographic, and Hematological Evaluations

All horses were subjected to a thorough physical examination [31,32,66]. Clinical examinations were performed after mechanical restraint without sedation. After that, an ECG evaluation was performed on horses in an orthostatic position in a quiet environment. The ECG recordings were acquired using a portable 12-channel digital electrocardiograph (TEB ECG Vet, Tecnologia Eletrônica Brasileira, São Paulo, SP, Brazil). Alligator metal clips embedded in alcohol were connected to the skin, and the electrodes were fixed. Electrodes were placed according to the Dubois configuration, placing electrodes one and two next to the spine tuberosity of both scapulae; electrode three on the xiphoid process of the sternum; and electrode four on the proximal cranial region of the left forelimb [67]. For recording, the speed was adjusted to 25 mm/s, the sensitivity was set at 1 cm = 1 mV, and bipolar (DI, DII, DIII) and augmented unipolar (aVR, aVL, aVF) leads were recorded. The parameters evaluated were cardiac rhythm, cardiac frequency, P (ms), P (mV), PR, QRS, and QT intervals, R and T waves, and ST segment levels. QRS polarity in the bipolar and unipolar augmented leads was used to determine the electric axis.
Blood samples were collected from the external jugular vein using vacuum tubes containing ethylenediaminetetraacetic acid (EDTA) or a clot activator (BD Vacutainer, Becton Dickinson, Curitiba, PR, Brazil). Whole blood samples collected with EDTA were used for hematological analyses using an automatic cell counter (pocH-100Iv-Diff, Sysmex, São Paulo, SP, Brazil). The parameters measured were red blood cell count (RBC), hemoglobin, packed cell volume (PCV), mean corpuscular volume (MCV), red blood cell distribution width (RDW), white blood cell count (WBC), lymphocytes and the sum of other WBCs, such as neutrophils, monocytes, and basophils (OTH), total platelet count (PLT), mean platelet volume (MPV), platelet distribution width (PDW), and platelet clump (P-LCR).
Serum samples were used for biochemical analyses using automated equipment (Cobas Mira Plus, Roche, Montclair, NJ, EUA). The measured parameters were alanine aminotransferase (ALT), aspartate transaminase (AST), alkaline phosphatase (ALP), gamma-glutamyl transpeptidase (GGT), urea, creatinine, total proteins (TP), albumin, globulins, glucose, amylase, cholesterol, triglyceride, lactate, lactate dehydrogenase (LDH), creatine kinase (CK), and creatine kinase/isoenzyme MB fraction (CK-MB).

5.3. Statistical Analysis

Statistical analyses were performed using the R software (version 3.6.1). The normality of data was evaluated using the Shapiro-Wilk test. The Mann–Whitney U test was used to compare non-parametric data (hematology, serum albumin and GGT), and Student’s t-test was employed to compare parametric data (all other parameters). The level of statistical significance was set at p < 0.05.

Author Contributions

Conceptualization, C.C.-O. and B.S.-B.; formal analysis, A.L.S.d.M.; investigation, A.L.S.d.M., B.C.A., J.C.M., S.d.A.L., A.F.M.B. and M.T.G.C.; writing—original draft preparation, A.L.S.d.M.; writing—review and editing, C.C.-O. and B.S.-B.; funding acquisition, J.C.M., C.C.-O. and B.S.-B. All authors have read and agreed to the published version of the manuscript.

Funding

This research was funded by the Coordenação de Aperfeiçoamento de Pessoal de Nível Superior–Brazil (CAPES) (Program COFECUB Process 88881.191812/2018-01), the Fundação de Amparo à Pesquisa do Estado de Minas Gerais–Brazil (FAPEMIG) (Process RED-00207-22), the Instituto Nacional de Ciência e Tecnologia em Venenos e Antivenenos (INCT-INOVATOX, Grant n◦ 406816/2022–0), the Conselho Nacional de Desenvolvimento Científico e Tecnológico–Brazil (CNPQ) (Process 311182/2017-8), the Centro de Produção e Pesquisa de Imunobiológicos (CPPI)—Secretaria de Saúde do Paraná, and by the Pró-Reitoria de Pesquisa of the Universidade Federal de Minas Gerais (Edital PRPq 02/2023).

Institutional Review Board Statement

The animal study protocol was approved by the Ethical Committee for the Use of Animals of the Universidade Federal de Minas Gerais—CEUA/UFMG (protocol code 159/2019, approved on 4 June 2018).

Informed Consent Statement

Not applicable.

Data Availability Statement

The datasets generated for this study are available on request from the corresponding author.

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Loden, J.K.; Seger, D.L.; Spiller, H.A.; Wang, L.; Byrne, D.W. Cutaneous-hemolytic loxoscelism following brown recluse spider envenomation: New understandings. Clin. Toxicol. (Phila.) 2020, 58, 1297–1305. [Google Scholar] [CrossRef]
  2. Miranda, A.L.S.; Guerra-Duarte, C.; Lima, S.A.; Chávez-Olórtegui, C.; Soto-Blanco, B. History, challenges and perspectives on Loxosceles (brown spiders) antivenom production in Brazil. Toxicon 2021, 192, 40–45. [Google Scholar] [CrossRef] [PubMed]
  3. Miranda, A.L.S.; Lima, S.D.; Botelho, A.F.M.; Campos, M.T.G.; Eckstein, C.; Minozzo, J.C.; Olortegui, C.C.; Soto-Blanco, B. Protective effectiveness of an immunization protocol against the toxic effects of Loxosceles intermedia venom in rabbits. Front. Vet. Sci. 2022, 9, 852917. [Google Scholar] [CrossRef] [PubMed]
  4. Silva, P.H.; da Silveira, R.B.; Appel, M.H.; Mangili, O.C.; Gremski, W.; Veiga, S.S. Brown spiders and loxoscelism. Toxicon 2004, 44, 693–709. [Google Scholar] [CrossRef] [PubMed]
  5. Swanson, D.L.; Vetter, R.S. Loxoscelism. Clin. Dermatol. 2006, 24, 213–221. [Google Scholar] [CrossRef] [PubMed]
  6. Chaim, O.M.; Trevisan-Silva, D.; Chaves-Moreira, D.; Wille, A.C.; Ferrer, V.P.; Matsubara, F.H.; Mangili, O.C.; da Silveira, R.B.; Gremski, L.H.; Gremski, W.; et al. Brown spider (Loxosceles genus) venom toxins: Tools for biological purposes. Toxins 2011, 3, 309–344. [Google Scholar] [CrossRef]
  7. Martins, G.C.; Melo, M.M.; Soto-Blanco, B. Araneísmo. Cadernos Técnicos de Veterinária e Zootecnia 2014, 75, 61–70. [Google Scholar]
  8. Gremski, L.H.; da Justa, H.C.; da Silva, T.P.; Polli, N.; Antunes, B.C.; Minozzo, J.C.; Wille, A.; Senff-Ribeiro, A.; Arni, R.K.; Veiga, S.S. Forty years of the description of brown spider venom Phospholipases-D. Toxins 2020, 12, 164. [Google Scholar] [CrossRef]
  9. Gremski, L.H.; Matsubara, F.H.; da Justa, H.C.; Schemczssen-Graeff, Z.; Baldissera, A.B.; Schluga, P.; Leite, I.O.; Boia-Ferreira, M.; Wille, A.; Senff-Ribeiro, A.; et al. Brown spider venom toxins: What are the functions of astacins, serine proteases, hyaluronidases, allergens, TCTP, serpins and knottins? J. Venom. Anim. Toxins Incl. Trop. Dis. 2021, 27, e20200188. [Google Scholar] [CrossRef]
  10. Ferrer, V.P.; de Mari, T.L.; Gremski, L.H.; Trevisan Silva, D.; da Silveira, R.B.; Gremski, W.; Chaim, O.M.; Senff-Ribeiro, A.; Nader, H.B.; Veiga, S.S. A novel hyaluronidase from brown spider (Loxosceles intermedia) venom (Dietrich’s Hyaluronidase): From cloning to functional characterization. PLoS Negl. Trop. Dis. 2013, 7, e2206. [Google Scholar] [CrossRef]
  11. Morgon, A.M.; Belisario-Ferrari, M.R.; Trevisan-Silva, D.; Meissner, G.O.; Vuitika, L.; Marin, B.; Tashima, A.K.; Gremski, L.H.; Gremski, W.; Senff-Ribeiro, A.; et al. Expression and immunological cross-reactivity of LALP3, a novel astacin-like metalloprotease from brown spider (Loxosceles intermedia) venom. Biochimie 2016, 128, 8–19. [Google Scholar] [CrossRef] [PubMed]
  12. Boia-Ferreira, M.; Moreno, K.G.; Basílio, A.; da Silva, L.P.; Vuitika, L.; Soley, B.; Wille, A.; Donatti, L.; Barbaro, K.C.; Chaim, O.M.; et al. TCTP from Loxosceles intermedia (brown spider) venom contributes to the allergic and inflammatory response of cutaneous loxoscelism. Cells 2019, 8, 1489. [Google Scholar] [CrossRef]
  13. Justa, H.; Matsubara, F.H.; de-Bona, E.; Schemczssen-Graeff, Z.; Polli, N.; de Mari, T.L.; Boia-Ferreira, M.; Minozzo, J.C.; Wille, A.; Senff-Ribeiro, A.; et al. LALLT (Loxosceles Allergen-Like Toxin) from the venom of Loxosceles intermedia: Recombinant expression in insect cells and characterization as a molecule with allergenic properties. Int. J. Biol. Macromol. 2020, 164, 3984–3999. [Google Scholar] [CrossRef] [PubMed]
  14. Hogan, C.J.; Barbaro, K.C.; Winkel, K. Loxoscelism: Old obstacles, new directions. Ann. Emerg. Med. 2004, 44, 608–624. [Google Scholar] [CrossRef] [PubMed]
  15. de Roodt, A.R.; Estevez-Ramírez, J.; Litwin, S.; Magaña, P.; Olvera, A.; Alagón, A. Toxicity of two North American Loxosceles (brown recluse spiders) venoms and their neutralization by antivenoms. Clin. Toxicol. 2007, 45, 678–687. [Google Scholar] [CrossRef]
  16. Gutiérrez, J.M.; Higashi, H.G.; Wen, F.H.; Burnouf, T. Strengthening antivenom production in Central and South American public laboratories: Report of a workshop. Toxicon 2007, 49, 30–35. [Google Scholar] [CrossRef]
  17. Gutiérrez, J.M.; Fan, H.W.; Silvera, C.L.; Angulo, Y. Stability, distribution and use of antivenoms for snakebite envenomation in Latin America: Report of a workshop. Toxicon 2009, 53, 625–630. [Google Scholar] [CrossRef]
  18. Waghmare, A.B.; Salvi, N.C.; Deopurkar, R.L.; Shenoy, P.A.; Sonpetkar, J.M. Evaluation of health status of horses immunized with snake venom and montanide adjuvants, IMS 3012 (nanoparticle), ISA 206 and ISA 35 (emulsion based) during polyvalent snake antivenom production: Hematological and biochemical assessment. Toxicon 2014, 82, 83–92. [Google Scholar] [CrossRef]
  19. Calabria, P.A.L.; Shimokava-Falcao, L.H.A.L.; Colombini, M.; Moura-da-Silva, A.M.; Barbaro, K.C.; Faquim-Mauro, E.L.; Magalhaes, G.S. Design and production of a recombinant hybrid toxin to raise protective antibodies against Loxosceles spider venom. Toxins 2019, 11, 108. [Google Scholar] [CrossRef]
  20. Angulo, Y.; Estrada, R.; Gutiérrez, J.M. Clinical and laboratory alterations in horses during immunization with snake venoms for the production of polyvalent (Crotalinae) antivenom. Toxicon 1997, 35, 81–90. [Google Scholar] [CrossRef]
  21. Miranda, A.L.S.; Antunes, B.C.; Minozzo, J.C.; Lima, S.A.; Botelho, A.F.M.; Campos, M.T.G.; Chávez-Olórtegui, C.D.; Soto-Blanco, B. Clinical effects of the immunization protocol using Loxosceles venom in naïve horses. Toxins 2022, 14, 338. [Google Scholar] [CrossRef] [PubMed]
  22. Pauli, I.; Puka, J.; Gubert, I.C.; Minozzo, J.C. The efficacy of antivenom in loxoscelism treatment. Toxicon 2006, 48, 123–137. [Google Scholar] [CrossRef] [PubMed]
  23. Pratanaphon, R.; Akesowan, S.; Khow, O.; Sriprapat, S.; Ratanabanangkoon, K. Production of highly potent horse antivenom against the Thai cobra (Naja kaouthia). Vaccine 1997, 15, 1523–1528. [Google Scholar] [CrossRef]
  24. Chotwiwatthanakun, C.; Pratanaphon, R.; Akesowan, S.; Sriprapat, S.; Ratanabanangkoon, K. Production of potent polyvalent antivenom against three elapid venoms using a low dose, low volume, multi-site immunization protocol. Toxicon 2001, 39, 1487–1494. [Google Scholar] [CrossRef] [PubMed]
  25. Figueiredo, L.F.; Dias-Lopes, C.; Alvarenga, L.M.; Mendes, T.M.; Machado-de-Ávila, R.A.; McCormack, J.; Minozzo, J.C.; Kalapothakis, E.; Chávez-Olórtegui, C. Innovative immunization protocols using chimeric recombinant protein for the production of polyspecific loxoscelic antivenom in horses. Toxicon 2014, 86, 59–67. [Google Scholar] [CrossRef] [PubMed]
  26. Billiau, A.; Matthys, P. Modes of action of Freund’s adjuvants in experimental models of autoimmune diseases. J. Leukoc. Biol. 2001, 70, 849–860. [Google Scholar] [CrossRef]
  27. Divers, T.J. Prevention and treatment of thrombosis, phlebitis, and laminitis in horses with gastrointestinal diseases. Vet. Clin. North Am. Equine Pract. 2003, 19, 779–790. [Google Scholar] [CrossRef]
  28. Milne, M.; Bradbury, L. The use of ultrasound to assess thrombogenic properties of teflon and polyurethane catheters for short-term use in systematically healthy horses. J. Equine Vet. Sci. 2009, 29, 833–841. [Google Scholar] [CrossRef]
  29. Dias, D.P.; de Lacerda Neto, J.C. Jugular thrombophlebitis in horses: A review of fibrinolysis, thrombus formation, and clinical management. Can. Vet. J. 2013, 54, 65–71. [Google Scholar]
  30. Kopper, J.J.; Bolger, M.E.; Kogan, C.J.; Schott, H.C., 2nd. Outcome and complications in horses administered sterile or non-sterile fluids intravenously. J. Vet. Intern. Med. 2019, 33, 2739–2745. [Google Scholar] [CrossRef]
  31. Speirs, V.C.; Wrigley, R.H. Clinical Examination of Horses; W.B. Saunders: Philadelphia, PA, USA, 1997; 358p. [Google Scholar]
  32. Costa, L.R.R.; Paradis, M.R. Manual of Clinical Procedures in the Horse; Wiley-Blackwell: Hoboken, NJ, USA, 2017; 680p. [Google Scholar]
  33. DeFranco, A.; Locksley, R.; Robertson, M. Immunity: The Immune Response to Infectious and Inflammatory Disease (Primers in Biology); Oxford University Press: Oxford, UK, 2007; 350p. [Google Scholar]
  34. Dias-Lopes, C.; Felicori, L.; Guimarães, G.; Gomes, E.R.; Roman-Campos, D.; Duarte, H.; Damasceno, D.; Martins, M.; Kalapothakis, E.; Almeida, A.P.; et al. Cardiotoxic effects of Loxosceles intermedia spider venom and the recombinant venom toxin rLiD1. Toxicon 2010, 56, 1426–1435. [Google Scholar] [CrossRef] [PubMed]
  35. Menzies-Gow, N. ECG interpretation in the horse. Practice 2001, 23, 454–459. [Google Scholar] [CrossRef]
  36. McSloy, A. Cardiac auscultation and diagnostics in the poorly performing horse. Companion Anim. 2011, 16, 4–7. [Google Scholar] [CrossRef]
  37. Raekallio, M. Long term ECG recording with Holter monitoring in clinically healthy horses. Acta Vet. Scand. 1992, 33, 71–75. [Google Scholar] [CrossRef] [PubMed]
  38. Nissen, S.D.; Weis, R.; Krag-Andersen, E.K.; Hesselkilde, E.M.; Isaksen, J.L.; Carstensen, H.; Kanters, J.K.; Linz, D.; Sanders, P.; Hopster-Iversen, C.; et al. Electrocardiographic characteristics of trained and untrained standardbred racehorses. J. Vet. Intern. Med. 2022, 36, 1119–1130. [Google Scholar] [CrossRef]
  39. Bomfim, M.M.; Sattin, W.R.; Carvalho, S.F.; Gobesso, A.A.O.; Dória, R.S.G.; Leite-Dellova, D.C.A. Physical and electrocardiographic evaluation of horses used for wagon traction. Arq. Bras. Med. Veterinária Zootec. 2017, 69, 371–376. [Google Scholar] [CrossRef]
  40. Diniz, M.P.; Michima, L.E.S.; Fernandes, W.R. Estudo eletrocardiográfico de equinos de salto sadios. Pesqui. Vet. Bras. 2011, 31, 355–361. [Google Scholar] [CrossRef]
  41. Durando, M.M. Clinical techniques for diagnosing cardiovascular abnormalities in performance horses. Clin. Tech. Equine Pract. 2003, 2, 266–277. [Google Scholar] [CrossRef]
  42. Barold, S.S.; Herweg, B. The effect of hyperkalaemia on cardiac rhythm devices. Europace 2014, 16, 467–476. [Google Scholar] [CrossRef]
  43. Chyu, K.Y.; Shah, P.K. Electrocardiograms in Critical Care Cardiology. JACC Case Rep. 2022, 4, 101632. [Google Scholar] [CrossRef]
  44. Fielding, C.L.; Pusterla, N.; Magdesian, K.G.; Higgins, J.C.; Meier, C.A. Rattlesnake envenomation in horses: 58 cases (1992–2009). J. Am. Vet. Med. Assoc. 2011, 238, 631–635. [Google Scholar] [CrossRef] [PubMed]
  45. Coudry, V.; Jean, D.; Desbois, C.; Tnibar, A.; Laugier, C.; George, C. Myocardial fibrosis in a horse with polymorphic ventricular tachycardia observed during general anesthesia. Can. Vet. J. 2007, 48, 623–626. [Google Scholar] [PubMed]
  46. Mitchell, K.J. Practical considerations for diagnosis and treatment of ventricular tachycardia in horses. Equine Vet. Educ. 2017, 29, 670–676. [Google Scholar] [CrossRef]
  47. Pratt, S.L.; Bowen, M.; Redpath, A. Resolution of sustained ventricular tachycardia in a horse presenting with colic with magnesium sulfate. Equine Vet. Educ. 2023, 35, e517–e521. [Google Scholar] [CrossRef]
  48. Pedersen, P.J.; Karlsson, M.; Flethøj, M.; Trachsel, D.S.; Kanters, J.K.; Klaerke, D.A.; Buhl, R. Differences in the electrocardiographic QT interval of various breeds of athletic horses during rest and exercise. J. Vet. Cardiol. 2016, 18, 255–264. [Google Scholar] [CrossRef]
  49. Pedersen, P.J.; Kanters, J.K.; Buhl, R.; Klaerke, D.A. Normal electrocardiographic QT interval in race-fit Standardbred horses at rest and its rate dependence during exercise. J. Vet. Cardiol. 2013, 15, 23–31. [Google Scholar] [CrossRef]
  50. Trachsel, D.S.; Calloe, K.J.; Rgensen, E.; Lunddahl, C.S.; Pedersen, P.J.; Kanters, J.R.K.; Klaerke, D.A.; Buhl, R. Evaluation of electrocardiographic repolarization parameters after administration of trimethoprim-sulfadiazine, detomidine, or their combination in horses. Am. J. Vet. Res. 2021, 82, 207–217. [Google Scholar] [CrossRef]
  51. Satué, K.; Hernández, A.; Muñoz, A. Physiological factors in the interpretation of equine hematological profile. In Hematology—Science and Practice; Lawrie, C., Ed.; InTech: Rijeka, Croatia, 2012; pp. 573–596. [Google Scholar]
  52. McFarlane, D.; Sellon, D.C.; Gaffney, D.; Hedgpeth, V.; Papich, M.; Gibbs, S. Hematologic and serum biochemical variables and plasma corticotropin concentration in healthy aged horses. Am. J. Vet. Res. 1998, 59, 1247–1251. [Google Scholar]
  53. Dodds, W.J. Hemostasis. In Clinical Biochemistry of Domestic Animals, 5th ed.; Kaneko, J.J., Harvey, J.W., Bruss, M.L., Eds.; Academic Press: New York, NY, USA, 1997; pp. 241–283. [Google Scholar]
  54. Betiol, P.S.; Távora, J.P.F.; Parra, A.C.; Sucupira, M.C.A.; Gregory, L. Serum evaluation of cholesterol and triglycerides of serum-producing horses fed concentrate with 15% or 22% of crude protein. Braz. J. Vet. Res. Anim. Sci. 2008, 45, S20–S26. [Google Scholar] [CrossRef]
  55. Netto, D.P.; Chiacchio, S.B.; Bicudo, P.L.; Alfieri, A.A.; Balarim, M.R.S.; Nascimento, N. Hematological changes in sheep inoculated with natural and Cobalt60-irradiated Crotalus durissus terrificus venom (Laurenti, 1768). J. Venom. Anim. Toxins Incl. Trop. Dis. 2004, 10, 34–52. [Google Scholar] [CrossRef]
  56. McCue, M.E.; Geor, R.J.; Schultz, N. Equine metabolic syndrome: A complex disease influenced by genetics and the environment. J. Equine Vet. Sci. 2015, 35, 367–375. [Google Scholar] [CrossRef]
  57. Argiroudis, S.A.; Kent, J.E.; Blackmore, D.J. Observations on isoenzymes of creatine kinase in equine serum and tissues. Equine Vet. J. 1982, 14, 317–321. [Google Scholar] [CrossRef]
  58. Piper, H.M.; Schwartz, P.; Spahr, R.; Hütter, J.F.; Spieckermann, P.G. Early enzyme release from myocardial cells is not due to irreversible cell damage. J. Mol. Cell. Cardiol. 1984, 16, 385–388. [Google Scholar] [CrossRef]
  59. Tharwat, M.; Al-Sobayil, F.; Buczinski, S. Influence of racing on the serum concentrations of the cardiac biomarkers troponin I and creatine kinase myocardial band (CK-MB) in racing greyhounds. Vet. J. 2013, 197, 900–902. [Google Scholar] [CrossRef] [PubMed]
  60. Lazarim, F.L.; Antunes-Neto, J.M.; da Silva, F.O.; Nunes, L.A.; Bassini-Cameron, A.; Cameron, L.C.; Alves, A.A.; Brenzikofer, R.; de Macedo, D.V. The upper values of plasma creatine kinase of professional soccer players during the Brazilian National Championship. J. Sci. Med. Sport. 2009, 12, 85–90. [Google Scholar] [CrossRef] [PubMed]
  61. Teixeira-Neto, A.R.; Ferraz, G.C.; Moscardini, A.R.C.; Balsamao, G.M.; Souza, J.C.F.; Queiroz-Neto, A. Alterations in muscular enzymes of horses competing long-distance endurance. Braz. J. Vet. Anim. Sci. 2008, 60, 543–549. [Google Scholar]
  62. Saavedra-Langer, R.; Costa, T.G.F.; Lima, S.A.; Costal-Oliveira, F.; Martins, C.A.; Machado-de-Ávila, R.A.; Minozzo, J.C.; Soccol, V.T.; Guerra-Duarte, C.; Kalapothakis, E.; et al. A prokaryote system optimization for rMEPLox expression: A promising non-toxic antigen for Loxosceles antivenom production. Int. J. Biol. Macromol. 2021, 187, 66–75. [Google Scholar] [CrossRef]
  63. Quispe, R.L.; Jaramillo, M.L.; Torres-Huaco, F.; Bonilla, C.; Isasi, J.; Guerra-Duarte, C.; Chávez-Olórtegui, C. Partial in vivo protection against Peruvian spider Loxosceles laeta venom by immunization with a multiepitopic protein (rMEPLox). Toxicon 2022, 215, 1–5. [Google Scholar] [CrossRef]
  64. Karim-Silva, S.; Becker-Finco, A.; Jiacomini, I.G.; Boursin, F.; Leroy, A.; Noiray, M.; de Moura, J.; Aubrey, N.; Billiald, P.; Alvarenga, L.M. Loxoscelism: Advances and challenges in the design of antibody fragments with therapeutic potential. Toxins 2020, 12, 256. [Google Scholar] [CrossRef]
  65. Pucca, M.B.; Cerni, F.A.; Janke, R.; Bermúdez-Méndez, E.; Ledsgaard, L.; Barbosa, J.E.; Laustsen, A.H. History of envenoming therapy and current perspectives. Front. Immunol. 2019, 10, 1598. [Google Scholar]
  66. Marr, C.; Bowen, M. Cardiology of the Horse, 2nd ed.; Saunders: Edinburgh, UK, 2011; 300p. [Google Scholar]
  67. da Costa, C.F.; Samesima, N.; Pastore, C.A. Cardiac mean electrical axis in thoroughbreds—Standardization by the Dubois lead positioning system. PLoS ONE 2017, 12, e0169619. [Google Scholar]
Toxins 15 00589 g001
Figure 1. Multiple subcutaneous abscesses formed at infiltration sites in a horse used to produce Loxosceles antivenom.
Figure 1. Multiple subcutaneous abscesses formed at infiltration sites in a horse used to produce Loxosceles antivenom.
Toxins 15 00589 g001
Toxins 15 00589 g002
Figure 2. ECG records from horses who had undergone from six to eight immunization cycles for Loxosceles antivenom production. (A) First-degree AV block. Note the increased PR interval (0.35 s) (black line). (B) Wandering atrial pacemaker. Notice the different P-wave morphology (arrows). (C) Second-degree AV block. Note that a P wave is not followed by a QRS complex (arrow) despite the maintenance of PP intervals. Recordings of the second deviation of the frontal plane (DII), with a velocity of 25 mm/s and amplitude 1 N.
Figure 2. ECG records from horses who had undergone from six to eight immunization cycles for Loxosceles antivenom production. (A) First-degree AV block. Note the increased PR interval (0.35 s) (black line). (B) Wandering atrial pacemaker. Notice the different P-wave morphology (arrows). (C) Second-degree AV block. Note that a P wave is not followed by a QRS complex (arrow) despite the maintenance of PP intervals. Recordings of the second deviation of the frontal plane (DII), with a velocity of 25 mm/s and amplitude 1 N.
Toxins 15 00589 g002
Table 1. ECG results from horses used in several immunization protocols for Loxosceles antivenom production (immunized group) and non-immunized horses (control group). Data are presented as mean ± SEM.
Table 1. ECG results from horses used in several immunization protocols for Loxosceles antivenom production (immunized group) and non-immunized horses (control group). Data are presented as mean ± SEM.
ECG ParameterControl GroupImmunized HorsesReference Values
Heart rate (bpm)56.0 ± 3.8045.9 ± 5.8128–40
P (ms)118.8 ± 6.50133.6 ± 10.9<160
P (mV)0.43 ± 0.020.43 ± 0.04
PR (ms)282.8 ± 20.6297.0 ± 18.2<500
QRS (ms)128.3 ± 6.93133.7 ± 5.03<140
R (mV)1.03 ± 0.150.73 ± 0.11
QT (ms)434.2 ± 18.8509.3 ± 23.2 *<600
T (mV)0.46 ± 0.040.30 ± 0.03 *
* Significant difference (p < 0.05, Student’s t-test) from the control group.
Table 2. Complete blood count panel of immunized horses using Loxosceles spp. venom (immunized group) and non-immunized horses (control group). Data are presented as mean ± SEM.
Table 2. Complete blood count panel of immunized horses using Loxosceles spp. venom (immunized group) and non-immunized horses (control group). Data are presented as mean ± SEM.
ParameterControl GroupImmunized HorsesReference Values
WBC (cell × 103/μL)11.4 ± 0.939.66 ± 0.835.20–13.9
RBC (cell × 106/μL)8.67 ± 0.486.61 ± 0.28 *6.4–10.0
PCV (%)39.8 ± 2.4933.9 ± 1.3132.0–47.0
MCV (fL)45.8 ± 0.5851.4 ± 1.16 *37.0–59.0
PLT (cell × 103/μL)114.2 ± 17.4113.4 ± 10.5120.0–256.0
Lymphocytes (%)33.5 ± 2.8930.1 ± 1.90
OTHR (%)66.5 ± 2.8969.9 ± 1.90
Eosinophils (%)0.00 ± 0.000.43 ± 0.43
LYM (cell × 103/μL)3.68 ± 0.313.03 ± 0.231.5–7.7
OTHR (cell × 103/μL)7.75 ± 0.886.83 ± 0.75
Eosinophils (cell × 103/μL)0.00 ± 0.000.04 ± 0.04
RDW-SD (fL)38.0 ± 0.6144.6 ± 1.12 *
RDW-CV (%)20.9 ± 0.2822.3 ± 0.40 *21.0–25.0
PDW (fL)9.78 ± 0.0912.0 ± 1.10
MPV (fL)8.23 ± 0.129.07 ± 0.385.3–7.8
P-LCR (%)6.70 ± 1.4317.9 ± 4.46 *
Red blood cell count (RBC); packed cell volume (PCV); mean corpuscular volume (MCV); white blood cell count (WBC); red blood cell distribution width (RDW); sum of other WBC, such as neutrophils, monocytes, and basophils (OTHR); total platelet count (PLT); platelet distribution width (PDW); mean platelet volume (MPV); platelet clump (P-LCR). * Significant difference (p < 0.05, Mann–Whitney U test) from the control group.
Table 3. Blood biochemical parameters of immunized horses using Loxosceles spp. venom (immunized group) and non-immunized horses (control group). Data are presented as mean ± SEM.
Table 3. Blood biochemical parameters of immunized horses using Loxosceles spp. venom (immunized group) and non-immunized horses (control group). Data are presented as mean ± SEM.
ParameterControl GroupImmunized HorsesReference Values
Urea (mg/dL)35.8 ± 1.3336.3 ± 3.5821.4–51.5
Creatinine (mg/dL)1.36 ± 0.111.16 ± 0.060.4–2.2
ALT (U/L)4.32 ± 1.0716.4 ± 2.68 *3.0–23.0
AST (U/L)155.3 ± 10.6223.7 ± 10.9 *226–336
ALP (U/L)159.3 ± 12.9237.5 ± 29.6 *86.0–295.0
GGT (U/L)10.4 ± 1.3224.0 ± 9.22 *6.0–32.0
Glucose (mg/dL)101.3 ± 7.97115.7 ± 11.762.0–134.0
TP (g/dL)8.90 ± 0.467.81 ± 0.206.0–8.0
Albumin (g/dL)3.63 ± 0.232.18 ± 0.08 *2.4–4.1
Globulin (g/dL)5.28 ± 0.355.63 ± 0.262.6–4.0
Cholesterol (mg/dl)91.4 ± 5.8979.3 ± 2.9675.0–150.0
Triglycerides (mg/dl)42.9 ± 3.0219.9 ± 2.86 *4.0–44.0
Alanine aminotransferase (ALT); aspartate transaminase (AST); alkaline phosphatase (ALP); gamma-glutamyl transpeptidase (GGT); total protein (TP); creatine kinase (CK). * Significant difference (p < 0.05, Mann–Whitney U test for GGT and albumin, Student’s t-test for the other parameters) from the control group.
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Miranda, A.L.S.d.; Antunes, B.C.; Minozzo, J.C.; Lima, S.d.A.; Botelho, A.F.M.; Campos, M.T.G.; Chávez-Olórtegui, C.; Soto-Blanco, B. The Health Status of Horses Used for at Least Six Complete Cycles of Loxoscelic Antivenom Production. Toxins 2023, 15, 589. https://doi.org/10.3390/toxins15100589

AMA Style

Miranda ALSd, Antunes BC, Minozzo JC, Lima SdA, Botelho AFM, Campos MTG, Chávez-Olórtegui C, Soto-Blanco B. The Health Status of Horses Used for at Least Six Complete Cycles of Loxoscelic Antivenom Production. Toxins. 2023; 15(10):589. https://doi.org/10.3390/toxins15100589

Chicago/Turabian Style

Miranda, Ana Luísa Soares de, Bruno Cesar Antunes, João Carlos Minozzo, Sabrina de Almeida Lima, Ana Flávia Machado Botelho, Marco Túlio Gomes Campos, Carlos Chávez-Olórtegui, and Benito Soto-Blanco. 2023. "The Health Status of Horses Used for at Least Six Complete Cycles of Loxoscelic Antivenom Production" Toxins 15, no. 10: 589. https://doi.org/10.3390/toxins15100589

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop